|
Age, years, mean ± SD
|
51.7 ± 9.1
|
42.9 ± 10.7
|
1.08 (1.06–1.09) by 1 year
|
|
Women, N (%)
|
136 (22.2%)
|
152 (32.0%)
|
0.81 (0.58–1.15) ref. men
|
|
BMI, Kg/m2, mean ± SD
|
25.2 ± 4.6
|
24.0 ± 3.2
|
1.17 (1.07–1.16) by 1 point
|
|
Smoking, N (%)
|
|
Never
|
113 (18.5%)
|
204 (43.0%)
|
1
|
|
Current
|
265 (43.3%)
|
195 (41.0%)
|
3.65 (2.54–5.24)
|
|
Former
|
133 (21.7%)
|
76 (16.0%)
|
1.77 (1.14–2.75)
|
|
Risk factor for HIV acquisition IVDU
|
203 (33.2%)
|
37 (7.8%)
|
3.19 (2.02–5.04) ref. other risk factors
|
|
CDC stage, N (%)
|
|
A
|
229 (37.4%)
|
266 (56.0%)
|
1
|
|
B
|
177 (28.9%)
|
117 (24.6%)
|
1.20 (0.83–1.74)
|
|
C
|
195 (31.9%)
|
83 (17.5%)
|
2.04 (1.38–3.02)
|
|
ART duration, years, median (IQR)
|
12 (6–17)
|
6 (2–11)
|
1.08 (1.02–1.13) by 2 years
|
|
Current CD4, < 200 cells/mm3, N (%)
|
42 (6.9%)
|
23 (4.8%)
|
1.97 (1.01–3.87) ref. ≥200 cells/mm3
|
|
ART naïve, N (%)
|
14 (2.3%)
|
29 (6.1%)
|
1.32 (0.56–3.10) ref. experienced
|
|
Nadir CD4, cells/mm3, median (IQR)
|
170 (70–290)
|
242 (105–364)
|
1.00 (0.96–1.05) by 50 cells/ mm3
|
|
CD4, cells/mm3, median (IQR)
|
636 (434–852)
|
623 (425–780)
|
1.02 (0.97–1.08) by 100 cells/ mm3
|
|
Current PI, N* (%)
|
272 (44.4%)
|
169 (35.6%)
|
1.16 (0.84–1.59) ref. no PI
|
|
Current NNRTI, N* (%)
|
238 (38.9%)
|
172 (36.2%)
|
1.07 (0.78–1.47) ref. no NNRTI
|
|
Current INSTI, N* (%)
|
179 (29.2%)
|
108 (22.7)
|
1.22 (0.86–1.75) ref. no INSTI
|
|
N. of drugs in ART regimen
|
|
0
|
27 (4.4%)
|
56 (11.8%)
|
ref.
|
|
1
|
24 (3.9%)
|
40 (8.4%)
|
0.72 (0.28–1.82)
|
|
2
|
89 (14.5%)
|
38 (8.0%)
|
1.72 (0.76–3.93)
|
|
3
|
447 (73.0%)
|
323 (68.0%)
|
1.24 (0.63–2.44)
|
|
>=4
|
25 (4.1%)
|
18 (3.8%)
|
1.33 (0.50–3.53)
|
| | | |
χ2 for trend p = 0.39
|
|
Glycemia, mg/dL, mean ± SD
|
96.3 ± 25.3
|
88.8 ± 12.0
|
1.06 (1.01–1.12) by 5 mg/dL
|
|
Total cholesterol, mg/dL, mean ± SD
|
192.2 ± 42.9
|
178.3 ± 38.2
|
1.05 (1.03–1.08) by 5 mg/dL
|
|
Triglycerides, mg/dL, median (IQR)
|
146 (98–201)
|
96 (70–128)
|
1.08 (1.05–1.10) by 10 mg/dL
|
